ERBB2 and neoplasm: Collectively, the data indicate that treatment with site-specific TH-Trastuzumab-MCC-CpG conjugate, but not stochastic Trastuzumab-MCC-CpG conjugate delays tumor growth in mice with B14.3 HER2 pulmonary tumors which correlated with the biological activities of these conjugates in the in vitro HER2 binding assay.